A number of research firms have changed their ratings and price targets for Johnson & Johnson (NYSE: JNJ):

  • 9/21/2016 – Johnson & Johnson was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $123.13 price target on the stock.
  • 9/20/2016 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. We believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record. However, challenges for the company remain in the form of generic competition, pricing pressure and pipeline setbacks. “
  • 9/19/2016 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $123.00 price target on the stock.
  • 9/13/2016 – Johnson & Johnson had its price target lowered by analysts at Jefferies Group from $119.00 to $115.00. They now have a “hold” rating on the stock.
  • 9/13/2016 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $133.00 price target on the stock. According to Zacks, “J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record. “
  • 9/11/2016 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Leerink Swann.
  • 9/7/2016 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at BTIG Research.
  • 8/25/2016 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at BTIG Research.
  • 8/22/2016 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $124.21 price target on the stock.
  • 8/19/2016 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $142.00 price target on the stock.
  • 8/8/2016 – Johnson & Johnson was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $124.21 price target on the stock.
  • 8/5/2016 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $139.00 price target on the stock. According to Zacks, “J&J delivered another strong quarter with both earnings and revenues beating estimates. The Pharma segment continues to perform well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. J&J also raised its outlook for 2016. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates are on the rise following second quarter results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J's diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record”
  • 8/4/2016 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J’s second quarter results were strong with the company beating on all fronts and raising its outlook for the year. The Pharma segment continues to perform well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J's diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record.”
  • 8/4/2016 – Johnson & Johnson had its price target raised by analysts at Jefferies Group from $113.00 to $119.00. They now have a “hold” rating on the stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.49% during midday trading on Friday, hitting $118.87. The stock had a trading volume of 1,757,941 shares. The stock has a market capitalization of $325.21 billion, a price-to-earnings ratio of 22.15 and a beta of 0.61. The company’s 50 day moving average price is $120.13 and its 200-day moving average price is $116.17. Johnson & Johnson has a 52 week low of $89.90 and a 52 week high of $126.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Equities analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $0.80 dividend. The ex-dividend date was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s payout ratio is presently 60.15%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.